BR112016021947A2 - Derivados de oxazol substituídos como inibidores de tirosina-quinase do baço - Google Patents

Derivados de oxazol substituídos como inibidores de tirosina-quinase do baço

Info

Publication number
BR112016021947A2
BR112016021947A2 BR112016021947A BR112016021947A BR112016021947A2 BR 112016021947 A2 BR112016021947 A2 BR 112016021947A2 BR 112016021947 A BR112016021947 A BR 112016021947A BR 112016021947 A BR112016021947 A BR 112016021947A BR 112016021947 A2 BR112016021947 A2 BR 112016021947A2
Authority
BR
Brazil
Prior art keywords
oxazole derivatives
substituted oxazole
tyrosine kinase
kinase inhibitors
spleen tyrosine
Prior art date
Application number
BR112016021947A
Other languages
English (en)
Inventor
Benjahad Abdellah
Martin Jason
Schalon Claire
Pez Didier
Chevenier Emmanuel
Sandrinelli Franck
Picoul Willy
Moussy Alain
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52697442&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016021947(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ab Science filed Critical Ab Science
Publication of BR112016021947A2 publication Critical patent/BR112016021947A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

DERIVADOS DE OXAZOL SUBSTITUÍDOS COMO INIBIDORES DE TIROSINAQUINASE DO BAÇO. A presente invenção se refere aos derivados de oxazol substituídos que, seletivamente,modulam, regulam e/ou inibem uma transdução de sinal mediada por algumas quinases ativas e/ou de proteína mutantes envolvendo uma variedade de doenças de animais e seres humanos, como proliferativo-celulares, metabólicas, autoimunes, alérgicas e doenças degenerativas. Em particular, os presentes compostos descritos são inibidores Syk.
BR112016021947A 2014-03-24 2015-03-23 Derivados de oxazol substituídos como inibidores de tirosina-quinase do baço BR112016021947A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969479P 2014-03-24 2014-03-24
PCT/EP2015/056047 WO2015144614A1 (en) 2014-03-24 2015-03-23 Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112016021947A2 true BR112016021947A2 (pt) 2017-08-15

Family

ID=52697442

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016021947A BR112016021947A2 (pt) 2014-03-24 2015-03-23 Derivados de oxazol substituídos como inibidores de tirosina-quinase do baço

Country Status (15)

Country Link
US (1) US10053455B2 (pt)
EP (1) EP3122744B1 (pt)
JP (1) JP2017508772A (pt)
KR (1) KR20160127826A (pt)
CN (1) CN106414433A (pt)
AU (1) AU2015238546A1 (pt)
BR (1) BR112016021947A2 (pt)
CA (1) CA2943316A1 (pt)
CL (1) CL2016002322A1 (pt)
IL (1) IL247867A0 (pt)
MX (1) MX2016012460A (pt)
PH (1) PH12016501797A1 (pt)
RU (1) RU2016139031A (pt)
SG (1) SG11201607525UA (pt)
WO (1) WO2015144614A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3053920B1 (en) * 2015-02-05 2020-04-08 AB Science Compounds with anti-tumoral activity
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740420A (en) 1967-11-28 1973-06-19 Crown Zellerbach Corp Pharmaceutical compositions with dimethyl sulfoxide
US3743727A (en) 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
CA1163561A (en) 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4411893A (en) 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
CA1236029A (en) 1984-05-14 1988-05-03 Edmund Sandborn Pharmaceutical solutions comprising dimethyl sulfoxide
US4615699A (en) 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
ATE451381T1 (de) * 2005-01-19 2009-12-15 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
GB0503962D0 (en) 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
US8735417B2 (en) * 2009-12-17 2014-05-27 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
AR079993A1 (es) 2010-01-12 2012-03-07 Ab Science Derivados de azol, composiciones farmaceuticas y sus usos para tratar trastornos mediados por una sobreactividad de quinasas
US20130225548A1 (en) * 2010-10-28 2013-08-29 Nippon Shinyaku Co., Ltd. Pyridine Derivative and Medicinal Agent
EP2863915B1 (en) * 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2014031438A2 (en) * 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS

Also Published As

Publication number Publication date
KR20160127826A (ko) 2016-11-04
US20180179195A1 (en) 2018-06-28
RU2016139031A (ru) 2018-04-25
MX2016012460A (es) 2017-05-04
SG11201607525UA (en) 2016-10-28
US10053455B2 (en) 2018-08-21
CL2016002322A1 (es) 2017-04-28
CN106414433A (zh) 2017-02-15
EP3122744A1 (en) 2017-02-01
EP3122744B1 (en) 2018-11-07
IL247867A0 (en) 2016-11-30
RU2016139031A3 (pt) 2018-10-19
AU2015238546A1 (en) 2016-09-22
WO2015144614A1 (en) 2015-10-01
CA2943316A1 (en) 2015-10-01
JP2017508772A (ja) 2017-03-30
PH12016501797A1 (en) 2016-11-21

Similar Documents

Publication Publication Date Title
EA201290600A1 (ru) Тиазольные и оксазольные ингибиторы киназы
CY1121359T1 (el) Ενωσεις ετεροαρυλιου για αναστολη κινασης
ECSP18066138A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
EA201990202A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
EA201600589A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
UY35798A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
BR112016025470A2 (pt) ?hdl terapêutico?
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
BR112013021675A2 (pt) compostos de triazolopiridina como inibidores de pim cinase
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112016019825A2 (pt) anticorpos do fator bb do complemento
BR112016021947A2 (pt) Derivados de oxazol substituídos como inibidores de tirosina-quinase do baço
BR112018070255A2 (pt) reprogramação cardíaca direta melhorada.
BR112017008707A2 (pt) ração de pré-mistura para aquacultura encapsulada
BR112017007860A2 (pt) método para tratar uma doença de gordura no fígado
DK3728410T3 (da) Fremgangsmåde til behandling af lignocelluloseholdig biomasse
BR112016022301A2 (pt) Controle de arroz vermelho com mesotriona
BR112018012922A2 (pt) fórmula infantil que compreende peptídeos de leite humano
DK3541948T3 (da) Fremgangsmåde til forbedring af næringsværdien af fermenteringsbiprodukter
BR112017013007A2 (pt) composições e métodos para melhorar características agronômicas de plantas
ZA201902715B (en) Enzyme composition for therapeutic management of muscle soreness
BR112018013888A2 (pt) aditivo para ração animal contendo diurnosid e/ou cestrumosid

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]